The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index; 1 of the 121 sources its claims cite were checked for support.
p53 at a glance
Open accessAbstract
Since its discovery in 1979, the role of the p53 protein in cancer has been studied intensively (Levine and Oren, 2009). p53 is a crucial tumor suppressor, long-recognized to suppress cancer through the induction of cell-cycle-arrest or apoptosis programs in response to a plethora of different cellular stress signals. Although this model paints a seemingly simple picture, the longer that p53 is studied, the more it confronts researchers with new questions about its functions and mechanisms of action. The tumor-suppressor function of p53 extends beyond the capacity to trigger cell-cycle arrest and apoptosis, and novel activities that impact tumor suppression are perpetually emerging, including the regulation of metabolism, autophagy and the oxidative status of the cell. Moreover, because it acts as a crucial node downstream of diverse stress signals, it is perhaps not surprising that p53 has been recently discovered to have broader roles in physiology and pathology. In this article and its accompanying poster, we outline the basic molecular and cellular functions of p53, describe the intricate network of p53 mediators, and provide insight into the roles of p53 in normal physiology and human disease.Analysis of human cancers reveals a fundamental role for p53 in tumor suppression. More than half of human cancers, of a wide variety of types, harbor p53 (TP53) mutations, and inheritance of a mutant p53 allele predisposes humans to the Li-Fraumeni cancer syndrome (Olivier et al., 2010). Unequivocal confirmation of the crucial role for p53 in tumor suppression was demonstrated by the completely penetrant cancer phenotype of p53-null mice (Kenzelmann Broz and Attardi, 2010). p53 restricts tumor development by serving as a sensor of cellular stress, responding to diverse signals, including DNA damage, hypoxia, oncogene expression, nutrient deprivation and ribosome dysfunction, and limiting the propagation of cells under these adverse conditions (Vousden and Prives, 2009). In metazoans, an ancestral function of p53 is thought to be its ability to trigger programmed cell death (also known as apoptosis) in response to DNA damage, as a measure to preserve the integrity of the germ line (Junttila and Evan, 2009; Lu and Abrams, 2006; Lu et al., 2009). Subsequently, with the evolution of longer-living organisms, p53 is thought to have acquired the ability to respond to oncogenic signals, promoting apoptosis or senescence – a permanent cell-cycle-arrest response – as a safeguard against neoplasia. Thus, in cells exposed to potent stress signals, p53 drives irreversible programs of apoptosis or senescence to cull irreparably damaged or malignant cells, for the ultimate benefit of the organism (Vousden and Prives, 2009). Alternatively, under conditions of low-level stress, p53 elicits protective, pro-survival responses, such as temporary cell-cycle arrest, DNA repair and antioxidant protein production, to maintain genome integrity and viability in cells that sustain limited, reparable damage. These various responses rely on the ability of p53 to function as a transcriptional activator of a panoply of target genes, although transactivation-independent activities ascribed to p53 can also contribute to p53-mediated responses, as highlighted below.Similarly to other transcription factors, p53 has a modular protein domain structure (Joerger and Fersht, 2007; Vousden and Prives, 2009). The N-terminus of p53 comprises two transcriptional activation domains (TADs), TAD1 and TAD2, which span amino acid residues 1-40 and 40-60, respectively. These domains can independently enhance transcription of p53 target genes by recruiting histone-modifying enzymes, components of the basal transcriptional machinery and coactivator complexes, such as STAGA and Mediator (Gamper and Roeder, 2008; Joerger and Fersht, 2007). C-terminal to the transactivation domains, between residues 60-95, lies the proline-rich domain (PRD), which was originally proposed to participate in protein-protein interactions on the basis of the presence of PxxP motifs that resemble Src homology 3 (SH3)-domain-binding regions (Toledo et al., 2006; Toledo et al., 2007). However, a structural function might be the main role of this domain because knock-in mice carrying proline-to-alanine point mutations in the putative protein-protein interaction sites of this domain appear normal, whereas complete domain deletion disrupts p53 tumor-suppressor function. The central core of p53, which spans residues 100-300, comprises the DNA-binding domain that is responsible for sequence-specific binding of the protein to p53 response elements in DNA. Most cancer-associated p53 mutations are missense mutations in this domain and incapacitate DNA binding, illuminating the key importance of DNA binding for p53-mediated tumor suppression. Tumor-derived p53 mutations either alter residues that are essential for direct contact with p53 response elements (contact mutants) or impair proper folding of
Overview
CoChat Summary
TL;DR
This review summarizes p53 as a central stress-sensing tumor suppressor, covering its protein domains, transcriptional and cytoplasmic functions, regulation by MDM2/MDMX, and broader roles in physiology and disease. It emphasizes that p53 outcomes are highly context-dependent and that its biology is more complex than the canonical cell-cycle-arrest/apoptosis model.
Key findings
- p53 is mutated in more than half of human cancers of many types; inherited mutant p53 predisposes to Li-Fraumeni syndrome, and p53-null mice have a completely penetrant cancer phenotype.
- p53 has a modular domain structure: TAD1 (residues 1–40), TAD2 (40–60), proline-rich domain (60–95), DNA-binding core (100–300), tetramerization domain (325–356), and C-terminal basic domain (363–393). The six most common cancer hotspot residues are R175, G245, R248, R249, R273 and R282.
- p53 binds response elements as a tetramer, classically two half sites of RRRCWWGYYY separated by 0–13 bp. Severe stress drives apoptosis or senescence; low-level stress promotes temporary arrest, DNA repair and antioxidant responses. p53 also has cytoplasmic roles in apoptosis and autophagy, metabolic effects, and non-cell-autonomous tumor-suppressive effects.
- MDM2 and MDMX regulate p53 levels and activity. Mdm2-null mice show very early embryonic lethality that is completely rescued by p53 loss; Mdmx-null mice show p53-dependent embryonic lethality later in embryogenesis. p53 also activates MDM2 transcription, forming a negative-feedback loop.
Methods
- Narrative review article with an accompanying poster; no primary experimental design, sample or new data are reported.
- Synthesizes published literature on p53 molecular and cellular functions, its regulators, and its roles in normal physiology and human disease.
- No systematic review, meta-analysis or quantitative synthesis methods are stated.
Limitations
- The authors state that capturing the complete complexity of p53 function is beyond the scope of the article; they note omitted topics including post-translational modifications, p53 polymorphisms, p53 isoforms, and p63/p73 family interplay.
- The text highlights unresolved or controversial areas, including pro-aging versus anti-aging roles of p53 in different mouse models, the dual role of autophagy in tumor suppression, uncertainty about the full importance of the MDMX-MDM2 interaction, complexity of C-terminal lysine modifications, and unknown significance of p53 isoforms.
- Evident from the text: as a narrative review, it does not provide a systematic search strategy, quantitative synthesis, or primary data, and many conclusions rely on cited reviews and model systems.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 68 Not checked · 34 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“exciting recent findings have shown that reactivation of p53 expression in mouse models induces tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
What the sources say
- Not checked yetcites Martins et al., 2006 source
- Not checked yetcites Ventura et al., 2007 source
- Supportedcites Xue et al., 2007 source
Our copy of Xue et al. (2007) states directly that reactivating endogenous p53 in p53-deficient tumours produces complete tumour regression in vivo: the Abstract reports 'even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions', and the results describe hepatocarcinomas involuting to near-undetectable levels within 12 days of Dox-mediated p53 restoration (p. 1, Fig. 1b) and regressing after only 4 days of Dox (p. 2, Fig. 1e), including in a subcutaneous setting and in tumours co-expressing activated Akt or oncogenic K-ras. The mechanism (senescence plus innate immune clearance) is additional detail not required by the citing sentence, which is offered as one of three mouse-model citations for p53 reactivation-induced regression. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In response to sustained or severe stress signals, p53 drives irreversible apoptosis or senescence programs.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, a major component of repression probably occurs through indirect mechanisms, such as by p53-dependent activation of microRNAs or lincRNAs that repress gene expression (Guttman et al., 2009; He et al., 2007; Menendez et al., 2009; Riley et al., 2008).”
What the sources say
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“p53 also has a complex role in regulating autophagy.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The central core of p53, which spans residues 100-300, comprises the DNA-binding domain that is responsible for sequence-specific binding of the protein to p53 response elements in DNA.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims
Create a free account to see all 103 claims and to verify the 108 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Citations
Cites
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., Huarte, M., Zuk, O., Carey, B. W., Cassady, J. P., et al. (2009) · Nature · doi:10.1038/nature07672 · Cited by 4,098
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“More than half of human cancers, of a wide variety of types, harbor p53 (TP53) mutations, and inheritance of a mutant p53 allele predisposes humans to the Li-Fraumeni cancer syndrome (Olivier et al., 2010).”
BackgroundSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Indeed, exciting recent findings have shown that reactivation of p53 expression in mouse models induces tumor regression (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
Backgroundp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Cited by
Items 201–300 of 404
Association of p53 Arg72Pro polymorphism with gastric cancer: a meta-analysis
Tang, W., Zhou, X., Nie, S., Yang, Z. G., Zhu, H., Wu, X., Zhao, R., & Luo, Y. (2012) · Biomarkers · doi:10.3109/1354750x.2012.704646 · Cited by 15
Eleftheriadis, T., Pissas, G., Sounidaki, M., Antoniadis, N., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1596-9 · Cited by 15
P53 Promotes Retinoid Acid-induced Smooth Muscle Cell Differentiation by Targeting Myocardin
Tan, Z., Li, J., Zhang, X., Yang, X., Zhang, Z., Yin, K., & Huang, H. (2018) · Stem Cells and Development · doi:10.1089/scd.2017.0244 · Cited by 15
Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis
Best, S. A., Vandenberg, C. J., Abad, E., Whitehead, L. W., Guiu, L., Ding, S., Brennan, M. S., Strasser, A., Herold, M. J., Sutherland, K. D., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03066-9 · Cited by 15
Kim, H., Lee, S. H., Lee, M.-N., Oh, G. T., Choi, K., & Choi, E. Y. (2013) · Oncotarget · doi:10.18632/oncotarget.1318 · Cited by 15
Frattini, A., Bolamperti, S., Valli, R., Cipolli, M., Pinto, R. M., Bergami, E., Frau, M. R., Cesaro, S., Signo, M., Bezzerri, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413331 · Cited by 14
Ahmed, E. Y., Latif, N. A. A., Nasr, T., Awad, H. M., & Abdelhafez, O. M. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14028 · Cited by 14
The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses
Cabrita, M. A., Bose, R., Vanzyl, E. J., Pastic, A., Marcellus, K. A., Pan, E., Hamill, J. D., & McKay, B. C. (2017) · Gene · doi:10.1016/j.gene.2017.01.018 · Cited by 14
Leptin protects placental cells from apoptosis induced by acidic stress
Pérez‐Pérez, A., Toro, A. R., Vilariño‐García, T., Guadix, P., Maymó, J. L., Dueñas, J. L., Varone, C. L., & Sánchez‐Margalet, V. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2940-9 · Cited by 14
Datta, P., Bang, S., Yue, Z., Beach, T., Stilgenbauer, M., Wang, H., Bowers, D. J., Kurokawa, M., Xiao, H., & Zheng, Y. (2020) · Dalton Transactions · doi:10.1039/d0dt01297a · Cited by 14
Argyle, D. J., & Khanna, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2362-5.00002-5 · Cited by 14
Sugden, M. C., & Holness, M. J. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00090.2012 · Cited by 14
Ferroptosis-associated signaling pathways and therapeutic approaches in depression
Feng, X., Zhang, W., Liu, X., Wang, Q., Dang, X., Han, J., & Zhang, X. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1559597 · Cited by 13
The Role of p53 in Nanoparticle-Based Therapy for Cancer
Szewczyk-Roszczenko, O. K., & Barlev, N. A. (2023) · Cells · doi:10.3390/cells12242803 · Cited by 13
Interaction between TP63 and MDM2 genes and the risk of recurrent pregnancy loss
Fraga, L. R., Boquett, J. A., Dutra, C. G., Vianna, F. S. L., Heck, C. F., Gonçalves, R. O., Paskulin, D. D., Costa, O. L. N., Ashton‐Prolla, P., Sanseverino, M. T. V., et al. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.07.044 · Cited by 13
Lao, X., Chen, Z., & Qin, A. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3923-7 · Cited by 13
Hossein, G., Azimian, V., & Fard, P. S. (2012) · PubMed Central · Cited by 13
Romero, M. A., Mobley, C. B., Mumford, P. W., Roberson, P. A., Haun, C. T., Kephart, W. C., Healy, J. C., Beck, D. T., Young, K. C., Martin, J. S., et al. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00192.2017 · Cited by 13
Nonlinearities in the cellular response to ionizing radiation and the role of p53 therein
Murray, D. L., & Mirzayans, R. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1721602 · Cited by 13
Recognition and Repair Pathways of Damaged DNA in Higher Plants
Biedermann, S., Mooney, S., & Hellm, H. (2011) · InTech eBooks · doi:10.5772/21380 · Cited by 19
Does expression of the retrogene UTP14c in the ovary pre-dispose women to ovarian cancer?
Rohozinski, J., Edwards, C. L., & Anderson, M. L. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2011.12.016 · Cited by 13
Reedich, E. J., Kalski, M., Armijo, N., Cox, G. A., & DiDonato, C. J. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113587 · Cited by 13
Li, C., Lee, H., Jung, J. H., Zhang, Y.-W., Wang, J., Liu, C., Sheffmaker, R. L., Segall, A. M., Zeng, S. X., & Lu, H. (2022) · Oncogene · doi:10.1038/s41388-022-02541-1 · Cited by 12
Aidemise, O. C., Patrick, I. S., & Avwioro, G. O. (2016) · Annals of Neurosciences · doi:10.1159/000449179 · Cited by 12
KIM, H.-N., Woo, H. Y., Do, S., & Kim, H. S. (2019) · In Vivo · doi:10.21873/invivo.11628 · Cited by 12
IL-6 deficiency attenuates p53 protein accumulation in aged male mouse hippocampus
Bialuk, I., Cieślińska, M., Kowalczuk, O., Bonda, T. A., Nikliński, J., & Winnicka, M. M. (2019) · Biogerontology · doi:10.1007/s10522-019-09841-2 · Cited by 12
Zeng, F., Yu, X., Sherry, J. P., Dixon, B., Duncker, B. P., & Bols, N. C. (2015) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2015.08.002 · Cited by 12
Guo, H.-R., Shen, S., Li, Y., Bi, R., Zhang, N.-N., Zheng, W., Deng, Y.-Y., Yang, Y., Yu, X., Wang, C.-X., et al. (2019) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2019.07.028 · Cited by 11
Gu, R., & Zhang, Q. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10447 · Cited by 12
Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes
Zheng, D.-J., Wang, X.-Y., Zhang, Z., Li, E.-Q., Yeung, C.-K., Borkar, R., Qin, G., Wu, Y.-J., & Xu, R.-H. (2022) · International Journal on Biological Sciences · doi:10.7150/ijbs.64640 · Cited by 11
Hefler, J., Wu, C., & Storey, K. B. (2015) · Biochemistry Research International · doi:10.1155/2015/731595 · Cited by 12
Khaksar, S., Kiarostami, K., & Ramdan, M. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103005 · Cited by 11
GART mediates the renewal of intestinal epithelial barrier via p38/p53/PUMA cascade in colitis
Bai, J., Hua, J., wei, S., Wang, S., Guo, H., & Tang, Q. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1301-y · Cited by 11
Langner, E., Jeleniewicz, W., Turski, W. A., & Plech, T. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.10.016 · Cited by 11
Mfossa, A. C. M., Verslegers, M., Verreet, T., bin Fida, H., Mysara, M., van IJcken, W. F. J., Vos, W. H. D., Moons, L., Baatout, S., Benotmane, M. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.171132 · Cited by 12
Chambon, L., Belgacem, I., & Gouzé, J. (2019) · Automatica · doi:10.1016/j.automatica.2019.108642 · Cited by 10
Control of negative feedback loops in genetic networks
Belgacem, I., Gouzé, J., & Edwards, R. (2020) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc42340.2020.9304088 · Cited by 10
Ye, C., Liu, S., Li, N., Zuo, S., Niu, Y., Lin, Q., Liang, H., Luo, X., & Fu, X. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02727-21 · Cited by 10
The status of p53 in cancer cells affects the role of autophagy in tumor radiosensitisation.
Zheng, R., Yao, Q., Du, S., Ren, C., Sun, Q., Xu, Z., Lin, X., & Yuan, Y. (2014) · PubMed · Cited by 10
Regulation of p53 in the red-eared slider (Trachemys scripta elegans) in response to salinity stress
Li, W., Li, N., Liang, L., Yu, Q., Ren, P., Shi, H., Storey, K. B., Hong, M., & Ding, L. (2019) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2019.03.011 · Cited by 10
Chitrala, K. N., Nagarkatti, M., Nagarkatti, P. S., & Yeguvapalli, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122962 · Cited by 10
Chen, T.-H., Wu, Y., Hou, J.-N., Chiang, Y., Cheng, C.-C., Sifiyatun, E., Chiu, C., Wang, L.-C., & Chen, W. (2018) · Virology · doi:10.1016/j.virol.2018.04.011 · Cited by 10
Does KRAS Play a Role in the Regulation of Colon Cancer Cells-Derived Exosomes?
Eng, S.-K., Imtiaz, I. R., Goh, B. H., Ming, L. C., Lim, Y. C., & Lee, W.-L. (2021) · Biology · doi:10.3390/biology10010058 · Cited by 9
Adenovirus Replaces Mitotic Checkpoint Controls
Turner, R. L., Groitl, P., Dobner, T., & Ornelles, D. A. (2015) · Journal of Virology · doi:10.1128/jvi.00213-15 · Cited by 9
Zhang, Z., Song, R., Xiao, X. I. N. G., Wang, L., & Niu, C. (2017) · Integrative Zoology · doi:10.1111/1749-4877.12261 · Cited by 9
p53 regulates DREAM complex-mediated repression in a p21-independent manner
Agrawal, R., & Sengupta, S. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00402-7 · Cited by 8
The p53 binding protein PDCD5 is not rate-limiting in DNA damage induced cell death
Bock, F. J., Tanzer, M. C., Haschka, M. D., Krumschnabel, G., Sohm, B., Goetsch, K., Kofler, R., & Villunger, A. (2015) · Scientific Reports · doi:10.1038/srep11268 · Cited by 8
Pissas, G., Tziastoudi, M., Divani, M., Poulianiti, C., Konsta, M. A. P., Lykotsetas, E., Liakopoulos, V., Stefanidis, I., & Eleftheriadis, T. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23854 · Cited by 9
Identification and characterization of Dicer1e, a Dicer1 protein variant, in oral cancer cells
Cantini, L. P., Andino, L. M., Attaway, C. C., Butler, B., Dumitriu, A., Blackshaw, A. M., & Jakymiw, A. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-190 · Cited by 8
Hosmani, J., Mushtaq, S., Abullais, S. S., Almubarak, H. M., Assiri, K. I., Testarelli, L., Mazzoni, A., & Patil, S. (2021) · Medicina · doi:10.3390/medicina57050438 · Cited by 8
Shen, H., Li, L., Teng, Z., Meng, T., Kong, X., Hu, Y. P., Zhu, Y. K., & Ma, L. (2019) · Scientific Reports · doi:10.1038/s41598-018-34904-8 · Cited by 8
Abdel-Rasol, M. A., El‐Beih, N. M., Yahya, S. M. M., Ismail, M. A., & El-Sayed, W. M. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191021162411 · Cited by 8
Ríos‐Pérez, L. D. L., Brunner, R. M., Hadlich, F., Rebl, A., Kühn, C., Wittenburg, D., Goldammer, T., & Verleih, M. (2020) · Genes · doi:10.3390/genes11080841 · Cited by 8
Simon, D. J., Belsky, D. M., Bowen, M. E., Ohn, C. Y. J., O’Rourke, M. K., Shen, R., Kım, G., Pitts, J., Attardi, L. D., & Tessier‐Lavigne, M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.03.011 · Cited by 8
Self-citationGirolamo, M. D. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_421 · Cited by 8
Holm, K. L., Syljuåsen, R. G., Hasvold, G., Alsøe, L., Nilsen, H. L., Ivanauskiene, K., Collas, P., Shaposhnikov, S. A., Collins, A. R., Indrevær, R. L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185708 · Cited by 8
Eleftheriadis, T., Pissas, G., Nikolaou, E., Filippidis, G., Liakopoulos, V., & Stefanidis, I. (2020) · Biomedical Reports · doi:10.3892/br.2020.1309 · Cited by 8
Proteasomal control of transcription factors: mechanisms, regulation and dysregulation
Larsen, F. B., Kragelund, B. B., Lindorff‐Larsen, K., Heidarsson, P. O., & Hartmann‐Petersen, R. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06103-6 · Cited by 7
Khaksar, S., Kiarostami, K., & Alinaghi, S. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02058-y · Cited by 7
Zhao, D.-M., Diao, Y., & Xu, Q. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s260209 · Cited by 7
Hops/Tmub1 Heterozygous Mouse Shows Haploinsufficiency Effect in Influencing p53-Mediated Apoptosis
Ferracchiato, S., Di-Iacovo, N., Scopetti, D., Piobbico, D., Castelli, M., Pieroni, S., Gargaro, M., Manni, G., Brancorsini, S., Fazia, M. A. D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137186 · Cited by 7
Pereg, D., Cohen, K., Mosseri, M., Berlin, T., Steinberg, D. M., Ellis, M. H., & Ashur‐Fabian, O. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29223 · Cited by 7
Post-transcriptional control of stress responses in cancer
Harvey, R. F., & Willis, A. E. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.006 · Cited by 7
The PURB–HOTAIR complex regulates p53-dependent promoter-specific transcriptional activation
Xia, Z., Kon, N., Su, Z., Yi, J., Xu, H. Z., Zhou, H., Zhang, Z., & Gu, W. J. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01597-3 · Cited by 6
Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2016) · International Urology and Nephrology · doi:10.1007/s11255-016-1247-6 · Cited by 6
Holme, J. A., Nyvold, H. E., Tat, V., Arlt, V. M., Bhargava, A., Gützkow, K. B., Solhaug, A., Låg, M., Becher, R., Schwarze, P. E., et al. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.07.009 · Cited by 6
What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
Eleftheriadis, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01879 · Cited by 6
Chen, Y., & Yu, T. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10003-w · Cited by 6
Frieden, B. R. (2021) · Handbook of statistics · doi:10.1016/bs.host.2021.07.002 · Cited by 6
Carrà, G., Russo, I., Guerrasio, A., & Morotti, A. (2019) · Cells · doi:10.3390/cells8101248 · Cited by 6
Kauntz, H. (2012) · theses.fr (ABES) · doi:10.70675/45aa02d4zd1a8z4db3z8a59zdbdbbc1ed4fc · Cited by 6
Vacas, E., Muñoz‐Moreno, L., Fernández‐Martínez, A. B., Bajo, A. M., Sánchez‐Chapado, M., Prieto, J. C., & Carmena, M. J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.05.036 · Cited by 5
An arresten-derived anti-angiogenic peptide triggers apoptotic cell death in endothelial cells
Chamani, R., Saberi, O., & Fathinejad, F. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09448-y · Cited by 5
p53 gene discriminates two ecologically divergent sister species of pine voles
Quina, A. S., Bastos‐Silveira, C., Miñarro, M., Ventura, J., Jiménez, R., Paulo, O. S., & Mathias, M. D. L. (2015) · Heredity · doi:10.1038/hdy.2015.44 · Cited by 5
Compound cellular stress maximizes apoptosis independently of p53 in glioblastoma
Ho, C.-J., Tsai, C.-Y., Zhu, W., Pao, Y., Chen, H.-W., Hu, C., Lee, Y.-L., Huang, T.-S., Chen, C., Loh, J., et al. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2041954 · Cited by 5
A Monoclonal Antibody against p53 Cross-Reacts with Processing Bodies
Thomas, M. G., Luchelli, L., Pascual, M. L., Gottifredi, V., & Boccaccio, G. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036447 · Cited by 5
Gong, D., Gu, J., Zhou, K., & Huang, W. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928273058231128073414 · Cited by 4
RETRACTED: UHRF2, another E3 ubiquitin ligase for p53
Bai, L., Wang, X., Jin, F., Yang, Y., Qian, G., & Duan, C. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.009 · Cited by 4
RetractedEmerging Therapeutic Targets for Soft Tissue Sarcoma
Smith, J., & Riedel, R. F. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0175-y · Cited by 4
A Novel Method to Analyze Nucleocytoplasmic Transport In Vivo by Using Short Peptide Tags
Wimmer, C., Platzer, S., Hillen, W., & Klotzsche, M. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.007 · Cited by 4
Tumour Biology: p53 Gene Mechanisms
Zulfin Shaikh Niranjan, K. C. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000344 · Cited by 4
Sacco, A., Kawano, Y., Moschetta, M., Zavidij, O., Huynh, D., Reagan, M. R., Mishima, Y., Manier, S., Park, J., Morgan, E. A., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24778 · Cited by 4
De la mesure en toute chose : dérégulation de p53, cancer et syndromes télomériques
Jaber, S., Simeonova, I., & Toledo, F. (2013) · médecine/sciences · doi:10.1051/medsci/20132912003 · Cited by 4
[Autophagy and immune response].
Peña, M. J., & Sanctis, J. B. D. (2013) · PubMed · Cited by 4
Liu, J., Wang, Q., Ni, X., Su, Q., Ning, Y., Xie, X., He, J., Yang, S., Yuan, R., & Gao, H. (2025) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2025.200237 · Cited by 3
Les liaisons dangereuses : p53, dyskératose congénitale et anémie de Fanconi
Toufektchan, E., Jaber, S., & Toledo, F. (2017) · médecine/sciences · doi:10.1051/medsci/20173301018 · Cited by 3
Frequency switching between oscillatory homeostats and the regulation of p53
Ruoff, P., & Nishiyama, N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227786 · Cited by 3
Nishimori, A., Andoh, K., Matsuura, Y., Okagawa, T., & Konnai, S. (2024) · mSphere · doi:10.1128/msphere.00216-24 · Cited by 3
DNA Damage: Cellular Responses, Repair, and Cancer Treatment
Cartwright, B. M., Musich, P. R., & Zou, Y. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-7296-3_6 · Cited by 3
Sadauskas‐Henrique, H., de Souza-Bastos, L. R., & da Silva, G. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821337-7.00001-3 · Cited by 4
Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
Ye, F., Wang, T., Liu, A., Li, Y., Li, N., Wang, H., & Chen, W.-M. (2021) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2021.2021.0064 · Cited by 3
Mao, G., Xu, W., Jamil, M., Zhang, W., Jiao, N., & Liu, Y. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010293337240312051931 · Cited by 3
Lee, J., Koo, G., Park, J., Han, B.-C., Kwon, M., & Lee, S. (2025) · FEBS Open Bio · doi:10.1002/2211-5463.70028 · Cited by 3
Cell Cycle and DNA Damage Response in Postmitotic Neurons
Kruman, I. I. (2011) · InTech eBooks · doi:10.5772/20859 · Cited by 3
Soto‐Mercado, V., Mendivil‐Perez, M., Urueña, C. P., Susana Fiorentino, G., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180426111520 · Cited by 3
Synthesis of eugenol esters derivatives as breast cancer drugs
Pangesti, D. P., Az-Zahra, N. F., Warsito, W., & Masruri, M. (2024) · AIP conference proceedings · doi:10.1063/5.0194082 · Cited by 2
Nabina, L., Mutum, R., Laishram, R. S., Persy, H., Rainy, R., & Hussain, S. M. A. (2024) · Indian Journal of Pathology and Oncology · doi:10.18231/j.ijpo.2024.057 · Cited by 2
Lo, C. S., Alavi, P., Bassey-Archibong, B. I., Jahroudi, N., & Pasdar, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306705 · Cited by 2
Ezenabor, E. H., Afolabi, A., Ojo, O. A., & Adeyemı, O. S. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-5876-5.ch008 · Cited by 2
El-Attar, M. M., Abdel-Tawab, F. M., Awad, A. A., Ahmad, E. S., Kamel, H. A., & Hassan, A. I. (2019) · Egyptian Journal of Genetics and Cytology · Cited by 2
Metadata
- Authors
- Brady, C. A., & Attardi, L. D.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Attardi, Laura D.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2010-08-01
- Volume
- 123
- Issue
- 15
- Pages
- 2527-2532
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- PMC
- PMC2912460
- OpenAlex
- W2170622332
- Cited by
- 403
- References
- 96
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 19 · 2023: 28 · 2022: 17 · 2021: 24 · 2020: 29 · 2019: 39 · 2018: 32 · 2017: 28 · 2016: 22 · 2015: 27 · 2014: 33 · 2013: 26 · 2012: 27
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Journal of Cell Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, tumor suppressor, TP53 mutation, Li-Fraumeni syndrome, cell cycle arrest, apoptosis, cellular stress response, DNA damage, hypoxia, oncogene-induced senescence, autophagy, cellular metabolism, oxidative stress, p53-null mice, cancer susceptibility
- MeSH terms
- Animals, Autophagy, Cytoplasm, Humans, Neoplasms, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-15, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-15 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.